CEO
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics develops novel small molecule inhibitors targeting the active states of RAS proteins and the RAS-PI3Kα interaction. Their pipeline aims to overcome limitations of current cancer therapies by maximizing target inhibition and addressing resistance mechanisms for RAS and PI3Kα-driven cancers.
- Biotechnology
Updated 5 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Problem
Cancers driven by RAS and PI3Kα mutations represent a significant unmet medical need, as current therapeutic strategies often exhibit limitations in efficacy and can lead to adaptive resistance mechanisms. Existing treatments may not fully address the active oncogenic states of these proteins, resulting in suboptimal patient outcomes.
Solution
BridgeBio Oncology Therapeutics (BBOT) is developing novel small molecule inhibitors designed to target the active ON and OFF states of RAS proteins, as well as the interaction between RAS and PI3Kα. Their approach aims to overcome the limitations of current therapies by maximizing target inhibition and addressing resistance pathways. By leveraging deep expertise in RAS signaling biology, BBOT is advancing a pipeline of rationally designed therapeutics with the goal of providing improved efficacy and safety profiles for patients with these aggressive cancers. The company's strategy focuses on translating scientific discoveries into clinical applications to deliver transformative medicines.
Target Audience
The primary target audience includes oncologists, clinical researchers, and pharmaceutical partners focused on developing and delivering advanced therapies for patients with RAS and PI3Kα-driven cancers.
Features
- **BBO-8520**: A direct inhibitor targeting both the ON and OFF states of KRAS, currently in Phase 1 clinical trials for KRAS G12C mutant non-small cell lung cancer (NSCLC).
- **BBO-10203**: An orally bioavailable small molecule designed to inhibit the physical interaction between RAS and PI3Kα, thereby blocking RAS-driven PI3Kα-AKT signaling. This candidate is in Phase 1 clinical trials for various breast cancers, colorectal cancer, and NSCLC.
- **BBO-11818**: A panKRAS inhibitor with high potency against KRAS G12D and KRAS G12V mutants, targeting both ON and OFF states of RAS. This candidate is in Phase 1 clinical trials for KRAS mutant solid tumors.
- **Targeting Active States**: Focus on inhibiting the active ON state of RAS, which is often a driver of resistance to existing therapies.
- **RAS-PI3Kα Interaction Inhibition**: Development of therapeutics that disrupt the interaction between RAS and PI3Kα, aiming for targeted efficacy without significant on-target toxicities like hyperglycemia.
- **Preclinical and Clinical Development**: Robust pipeline with candidates progressing through various stages of clinical development, supported by extensive preclinical data.